KLI
HIV

Kelman-Lazarov Inc’s CALYPTE BIOMEDICAL CORP NEW HIV Stock Holding History

Kelman-Lazarov Inc’s Portfolio HIV Stock Details HIV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-3,500
Closed – – 389
2016
Q3 		$0 Buy
+3,500
New – ﹤0.01% 399

Kelman-Lazarov Inc's HIV Position: Q4 2016 in Review

Kelman-Lazarov Inc sold out of CALYPTE BIOMEDICAL CORP NEW (HIV) in Q4 2016, closing a stake of 3,500 shares.

Kelman-Lazarov Inc first reported a position in HIV in Q3 2016 and held it in 1 quarter. The position peaked at $0 in Q3 2016. 1 fund tracked by Wall St. Rank holds HIV as of Q4 2016.

  • Kelman-Lazarov Inc reported no remaining CALYPTE BIOMEDICAL CORP NEW position as of Q4 2016 after selling out during the quarter.
  • Kelman-Lazarov Inc sold 3,500 CALYPTE BIOMEDICAL CORP NEW shares in Q4 2016.
  • Kelman-Lazarov Inc first reported a position in CALYPTE BIOMEDICAL CORP NEW in Q3 2016 and held it in 1 quarter.
  • Kelman-Lazarov Inc's CALYPTE BIOMEDICAL CORP NEW position peaked at $0 in Q3 2016.
  • 1 fund tracked by Wall St. Rank held CALYPTE BIOMEDICAL CORP NEW as of Q4 2016.

Based on Kelman-Lazarov Inc's 13F filing for Q4 2016, filed 17 Jan 2017.